Trial Outcomes & Findings for The Efficacy of Aerobic Exercise Training on ANS and Endothelial Function in Compensated Cirrhosis (NCT NCT06288828)
NCT ID: NCT06288828
Last Updated: 2026-05-22
Results Overview
Heart rate variability (HRV) was assessed using a 15-minute resting ECG recording. This table reports three time-domain measures: 1) SDNN (Standard deviation of all NN intervals), 2) RMSSD (Root mean square of successive differences), and 3) SDANN (Standard deviation of the average NN intervals). These parameters reflect autonomic nervous system activity and cardiac vagal tone. All data are reported in milliseconds. Higher values indicate better autonomic regulation. Only these three time-domain parameters are presented in this table.
COMPLETED
NA
50 participants
Change from Baseline (week 0) at Week 16
2026-05-22
Participant Flow
Participants were recruited from patients attending the Liver Unit of the Division of Gastroenterology, Department of Medicine, at King Chulalongkorn Memorial Hospital. The recruitment period spanned from March 12, 2024, to June 30, 2025.
A total of 525 patients who visited the Liver Unit, Division of Gastroenterology, at King Chulalongkorn Memorial Hospital were screened for eligibility. Potential participants were evaluated based on the inclusion and exclusion criteria. Of those screened, 475 patients were excluded prior to randomization: 303 did not meet the specific study criteria, and 172 declined to participate in the study for personal reasons or lack of interest in the intervention
Participant milestones
| Measure |
Aerobic Exercise Group (AE)
Participants in this group began the study with an initial enrollment of 25 individuals. Of these, 23 participants successfully completed the 16-week supervised exercise program. Two participants were withdrawn during the study period: one was lost to follow-up (could not be contacted), and one was excluded due to an intercurrent event (new-onset atrial fibrillation).
The intervention consisted of 150 minutes per week of brisk walking at a moderate intensity (RPE 12-15), designed to improve cardiovascular fitness and autonomic function. During the initial four weeks, the program followed a hybrid model-combining once-weekly hospital-based sessions with home-based exercise-followed by 12 weeks of exclusively home-based sessions.
Additionally, participants received individualized dietary counseling at baseline, week 8, and upon study completion. These nutritional recommendations were aimed at meeting daily energy and protein targets of 35 kcal/kg and 1.2 g/kg of body weight, respectively. Clinical assessments-including Heart Rate Variability (HRV), the Ewing battery, Flow-Mediated Dilation (FMD), and splanchnic circulation parameters-were performed at baseline and at the conclusion of the 16-week period.
|
Control Group (CG)
Participants in this group began the study with an initial enrollment of 25 individuals. Of these, 21 participants successfully completed the 16-week study period. Four participants were withdrawn: three declined further follow-up (withdrawal by subject), and one was excluded due to an intercurrent event (anemia).
Participants received standard medical care for compensated cirrhosis and were instructed to maintain their usual physical activity levels throughout the 16-week period. No structured or supervised exercise intervention was provided.
To ensure consistency between groups, participants also received individualized dietary counseling at baseline, week 8, and upon study completion. These nutritional recommendations targeted a daily energy intake of 35 kcal/kg and a protein intake of 1.2 g/kg of body weight. Clinical assessments-including Heart Rate Variability (HRV), the Ewing battery, Flow-Mediated Dilation (FMD), and splanchnic circulation parameters-were performed at baseline and at the conclusion of the 16-week period.
|
|---|---|---|
|
Overall Study
STARTED
|
25
|
25
|
|
Overall Study
COMPLETED
|
23
|
21
|
|
Overall Study
NOT COMPLETED
|
2
|
4
|
Reasons for withdrawal
| Measure |
Aerobic Exercise Group (AE)
Participants in this group began the study with an initial enrollment of 25 individuals. Of these, 23 participants successfully completed the 16-week supervised exercise program. Two participants were withdrawn during the study period: one was lost to follow-up (could not be contacted), and one was excluded due to an intercurrent event (new-onset atrial fibrillation).
The intervention consisted of 150 minutes per week of brisk walking at a moderate intensity (RPE 12-15), designed to improve cardiovascular fitness and autonomic function. During the initial four weeks, the program followed a hybrid model-combining once-weekly hospital-based sessions with home-based exercise-followed by 12 weeks of exclusively home-based sessions.
Additionally, participants received individualized dietary counseling at baseline, week 8, and upon study completion. These nutritional recommendations were aimed at meeting daily energy and protein targets of 35 kcal/kg and 1.2 g/kg of body weight, respectively. Clinical assessments-including Heart Rate Variability (HRV), the Ewing battery, Flow-Mediated Dilation (FMD), and splanchnic circulation parameters-were performed at baseline and at the conclusion of the 16-week period.
|
Control Group (CG)
Participants in this group began the study with an initial enrollment of 25 individuals. Of these, 21 participants successfully completed the 16-week study period. Four participants were withdrawn: three declined further follow-up (withdrawal by subject), and one was excluded due to an intercurrent event (anemia).
Participants received standard medical care for compensated cirrhosis and were instructed to maintain their usual physical activity levels throughout the 16-week period. No structured or supervised exercise intervention was provided.
To ensure consistency between groups, participants also received individualized dietary counseling at baseline, week 8, and upon study completion. These nutritional recommendations targeted a daily energy intake of 35 kcal/kg and a protein intake of 1.2 g/kg of body weight. Clinical assessments-including Heart Rate Variability (HRV), the Ewing battery, Flow-Mediated Dilation (FMD), and splanchnic circulation parameters-were performed at baseline and at the conclusion of the 16-week period.
|
|---|---|---|
|
Overall Study
Lost to Follow-up
|
1
|
3
|
|
Overall Study
intercurrent event
|
1
|
1
|
Baseline Characteristics
Assessment of body composition parameters via Bioelectrical Impedance Analysis (BIA) and Dual-energy X-ray Absorptiometry (DXA).
Baseline characteristics by cohort
| Measure |
Aerobic Exercise Group (AE)
n=25 Participants
Participants in this group began the study with an initial enrollment of 25 individuals. Of these, 23 participants successfully completed the 16-week supervised exercise program. Two participants were withdrawn during the study period: one was lost to follow-up (could not be contacted), and one was excluded due to an intercurrent event (new-onset atrial fibrillation).
The intervention consisted of 150 minutes per week of brisk walking at a moderate intensity (RPE 12-15), designed to improve cardiovascular fitness and autonomic function. During the initial four weeks, the program followed a hybrid model-combining once-weekly hospital-based sessions with home-based exercise-followed by 12 weeks of exclusively home-based sessions.
Additionally, participants received individualized dietary counseling at baseline, week 8, and upon study completion. These nutritional recommendations were aimed at meeting daily energy and protein targets of 35 kcal/kg and 1.2 g/kg of body weight, respectively. Clinical assessments-including Heart Rate Variability (HRV), the Ewing battery, Flow-Mediated Dilation (FMD), and splanchnic circulation parameters-were performed at baseline and at the conclusion of the 16-week period.
|
Control Group (CG)
n=25 Participants
Participants in this group began the study with an initial enrollment of 25 individuals. Of these, 21 participants successfully completed the 16-week study period. Four participants were withdrawn: three declined further follow-up (withdrawal by subject), and one was excluded due to an intercurrent event (anemia).
Participants received standard medical care for compensated cirrhosis and were instructed to maintain their usual physical activity levels throughout the 16-week period. No structured or supervised exercise intervention was provided.
To ensure consistency between groups, participants also received individualized dietary counseling at baseline, week 8, and upon study completion. These nutritional recommendations targeted a daily energy intake of 35 kcal/kg and a protein intake of 1.2 g/kg of body weight. Clinical assessments-including Heart Rate Variability (HRV), the Ewing battery, Flow-Mediated Dilation (FMD), and splanchnic circulation parameters-were performed at baseline and at the conclusion of the 16-week period.
|
Total
n=50 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
62.00 years
STANDARD_DEVIATION 7.61 • n=2 Participants
|
63.16 years
STANDARD_DEVIATION 6.37 • n=4 Participants
|
62.58 years
STANDARD_DEVIATION 6.97 • n=6 Participants
|
|
Sex: Female, Male
Female
|
19 Participants
n=2 Participants
|
11 Participants
n=4 Participants
|
30 Participants
n=6 Participants
|
|
Sex: Female, Male
Male
|
6 Participants
n=2 Participants
|
14 Participants
n=4 Participants
|
20 Participants
n=6 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=2 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=6 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
25 Participants
n=2 Participants
|
25 Participants
n=4 Participants
|
50 Participants
n=6 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=2 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=6 Participants
|
|
Child-Pugh score
score 5
|
22 Participants
n=2 Participants
|
25 Participants
n=4 Participants
|
47 Participants
n=6 Participants
|
|
Child-Pugh score
score 6
|
3 Participants
n=2 Participants
|
0 Participants
n=4 Participants
|
3 Participants
n=6 Participants
|
|
Etiologies of cirrhosis
Hepatitis B
|
6 Participants
n=2 Participants
|
17 Participants
n=4 Participants
|
23 Participants
n=6 Participants
|
|
Etiologies of cirrhosis
Hepatitis C
|
10 Participants
n=2 Participants
|
7 Participants
n=4 Participants
|
17 Participants
n=6 Participants
|
|
Etiologies of cirrhosis
Non-alcoholic steatohepatitis (NASH)
|
9 Participants
n=2 Participants
|
6 Participants
n=4 Participants
|
15 Participants
n=6 Participants
|
|
Etiologies of cirrhosis
Autoimmune hepatitis
|
3 Participants
n=2 Participants
|
1 Participants
n=4 Participants
|
4 Participants
n=6 Participants
|
|
Etiologies of cirrhosis
Alcoholic cirrhosis
|
1 Participants
n=2 Participants
|
1 Participants
n=4 Participants
|
2 Participants
n=6 Participants
|
|
Etiologies of cirrhosis
others
|
0 Participants
n=2 Participants
|
1 Participants
n=4 Participants
|
1 Participants
n=6 Participants
|
|
Autonomic function test : Ewing autonomic battery test
No dysfunction
|
8 Participants
n=2 Participants
|
6 Participants
n=4 Participants
|
14 Participants
n=6 Participants
|
|
Autonomic function test : Ewing autonomic battery test
Mild dysfunction
|
7 Participants
n=2 Participants
|
9 Participants
n=4 Participants
|
16 Participants
n=6 Participants
|
|
Autonomic function test : Ewing autonomic battery test
Moderate dysfunction
|
7 Participants
n=2 Participants
|
4 Participants
n=4 Participants
|
11 Participants
n=6 Participants
|
|
Autonomic function test : Ewing autonomic battery test
Severe dysfunction
|
3 Participants
n=2 Participants
|
6 Participants
n=4 Participants
|
9 Participants
n=6 Participants
|
|
Appendicular mass/height^2 from DXA
|
6.13 kg/m^2
STANDARD_DEVIATION 1.02 • n=2 Participants
|
6.51 kg/m^2
STANDARD_DEVIATION 0.94 • n=4 Participants
|
6.32 kg/m^2
STANDARD_DEVIATION 0.98 • n=6 Participants
|
|
Total Fat Mass from DXA
|
39.10 kilograms
STANDARD_DEVIATION 8.39 • n=2 Participants
|
36.69 kilograms
STANDARD_DEVIATION 8.89 • n=4 Participants
|
37.90 kilograms
STANDARD_DEVIATION 8.64 • n=6 Participants
|
|
Body composion
Skeletal muscle mass from BIA
|
22.65 Kilograms
STANDARD_DEVIATION 4.99 • n=2 Participants • Assessment of body composition parameters via Bioelectrical Impedance Analysis (BIA) and Dual-energy X-ray Absorptiometry (DXA).
|
25.48 Kilograms
STANDARD_DEVIATION 5.17 • n=4 Participants • Assessment of body composition parameters via Bioelectrical Impedance Analysis (BIA) and Dual-energy X-ray Absorptiometry (DXA).
|
24.07 Kilograms
STANDARD_DEVIATION 5.08 • n=6 Participants • Assessment of body composition parameters via Bioelectrical Impedance Analysis (BIA) and Dual-energy X-ray Absorptiometry (DXA).
|
|
Body composion
Fat Mass from BIA
|
21.72 Kilograms
STANDARD_DEVIATION 8.50 • n=2 Participants • Assessment of body composition parameters via Bioelectrical Impedance Analysis (BIA) and Dual-energy X-ray Absorptiometry (DXA).
|
23.91 Kilograms
STANDARD_DEVIATION 8.94 • n=4 Participants • Assessment of body composition parameters via Bioelectrical Impedance Analysis (BIA) and Dual-energy X-ray Absorptiometry (DXA).
|
22.82 Kilograms
STANDARD_DEVIATION 8.72 • n=6 Participants • Assessment of body composition parameters via Bioelectrical Impedance Analysis (BIA) and Dual-energy X-ray Absorptiometry (DXA).
|
|
Body composion
Total Fat Mass from DXA
|
35.81 Kilograms
STANDARD_DEVIATION 7.56 • n=2 Participants • Assessment of body composition parameters via Bioelectrical Impedance Analysis (BIA) and Dual-energy X-ray Absorptiometry (DXA).
|
41.16 Kilograms
STANDARD_DEVIATION 7.56 • n=4 Participants • Assessment of body composition parameters via Bioelectrical Impedance Analysis (BIA) and Dual-energy X-ray Absorptiometry (DXA).
|
38.49 Kilograms
STANDARD_DEVIATION 7.56 • n=6 Participants • Assessment of body composition parameters via Bioelectrical Impedance Analysis (BIA) and Dual-energy X-ray Absorptiometry (DXA).
|
|
6-Minute Walk test (6MWT)
|
377.84 meters
STANDARD_DEVIATION 68.76 • n=2 Participants
|
391.39 meters
STANDARD_DEVIATION 91.64 • n=4 Participants
|
384.62 meters
STANDARD_DEVIATION 81.01 • n=6 Participants
|
|
Handgrip strength
|
26.35 kilograms
STANDARD_DEVIATION 7.85 • n=2 Participants
|
31.37 kilograms
STANDARD_DEVIATION 8.69 • n=4 Participants
|
28.86 kilograms
STANDARD_DEVIATION 8.28 • n=6 Participants
|
|
Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT)
AST
|
42.60 U/L
STANDARD_DEVIATION 17.66 • n=2 Participants
|
32.40 U/L
STANDARD_DEVIATION 8.86 • n=4 Participants
|
37.50 U/L
STANDARD_DEVIATION 13.97 • n=6 Participants
|
|
Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT)
ALT
|
36.08 U/L
STANDARD_DEVIATION 18.25 • n=2 Participants
|
26.96 U/L
STANDARD_DEVIATION 11.78 • n=4 Participants
|
31.52 U/L
STANDARD_DEVIATION 15.02 • n=6 Participants
|
|
Serum ammonia
|
43.52 µmol/L
STANDARD_DEVIATION 11.99 • n=2 Participants
|
50.18 µmol/L
STANDARD_DEVIATION 26.83 • n=4 Participants
|
46.85 µmol/L
STANDARD_DEVIATION 20.78 • n=6 Participants
|
|
Heart Rate Variability (HRV): Time-Domain Measures including SDNN, SDANN, RMSSD
SDNN
|
82.18 milliseconds
n=2 Participants
|
67.05 milliseconds
n=4 Participants
|
75.87 milliseconds
n=6 Participants
|
|
Heart Rate Variability (HRV): Time-Domain Measures including SDNN, SDANN, RMSSD
SDANN
|
62.73 milliseconds
n=2 Participants
|
58.91 milliseconds
n=4 Participants
|
62.73 milliseconds
n=6 Participants
|
|
Heart Rate Variability (HRV): Time-Domain Measures including SDNN, SDANN, RMSSD
RMSSD
|
65.46 milliseconds
n=2 Participants
|
51.74 milliseconds
n=4 Participants
|
62.70 milliseconds
n=6 Participants
|
|
pNN50
|
11.51 %
n=2 Participants
|
3.37 %
n=4 Participants
|
9.42 %
n=6 Participants
|
|
Heart Rate Variability (HRV): Frequency Domain Measures
Total power (TP)
|
5972.44 ms^2
n=2 Participants
|
4259.97 ms^2
n=4 Participants
|
4449.37 ms^2
n=6 Participants
|
|
Heart Rate Variability (HRV): Frequency Domain Measures
High Frequency (HF) Power
|
1445.00 ms^2
n=2 Participants
|
680.14 ms^2
n=4 Participants
|
1024.34 ms^2
n=6 Participants
|
|
Heart Rate Variability (HRV): Frequency Domain Measures
Low Frequency (LF) Power
|
1074.85 ms^2
n=2 Participants
|
1018.52 ms^2
n=4 Participants
|
1074.85 ms^2
n=6 Participants
|
|
Heart Rate Variability (HRV): Frequency Domain Measures
Very Low Frequency (VLF) Power
|
1333.62 ms^2
n=2 Participants
|
1437.87 ms^2
n=4 Participants
|
1340.61 ms^2
n=6 Participants
|
|
LF/HF Ratio (Low Frequency/High Frequency Ratio)
|
0.46 Ratio
n=2 Participants
|
0.93 Ratio
n=4 Participants
|
0.58 Ratio
n=6 Participants
|
|
Flow-mediated Dilation (FMD)
|
5.62 Percent
STANDARD_DEVIATION 3.62 • n=2 Participants
|
6.80 Percent
STANDARD_DEVIATION 3.92 • n=4 Participants
|
6.21 Percent
STANDARD_DEVIATION 3.77 • n=6 Participants
|
|
Splanchnic Vascular Velocity
Superior Mesenteric Artery: PSV
|
169.91 centimeters per second (cm/s)
STANDARD_DEVIATION 40.70 • n=2 Participants
|
178.18 centimeters per second (cm/s)
STANDARD_DEVIATION 40.17 • n=4 Participants
|
174.05 centimeters per second (cm/s)
STANDARD_DEVIATION 40.24 • n=6 Participants
|
|
Splanchnic Vascular Velocity
Superior Mesenteric Artery: EDV
|
21.98 centimeters per second (cm/s)
STANDARD_DEVIATION 11.63 • n=2 Participants
|
27.84 centimeters per second (cm/s)
STANDARD_DEVIATION 12.49 • n=4 Participants
|
24.91 centimeters per second (cm/s)
STANDARD_DEVIATION 12.33 • n=6 Participants
|
|
Splanchnic Vascular Velocity
Superior Mesenteric Artery: TAMAX
|
59.97 centimeters per second (cm/s)
STANDARD_DEVIATION 18.34 • n=2 Participants
|
65.38 centimeters per second (cm/s)
STANDARD_DEVIATION 19.32 • n=4 Participants
|
62.68 centimeters per second (cm/s)
STANDARD_DEVIATION 18.83 • n=6 Participants
|
|
Splanchnic Vascular Velocity
Celiac Artery: PSV
|
172.29 centimeters per second (cm/s)
STANDARD_DEVIATION 60.81 • n=2 Participants
|
184.19 centimeters per second (cm/s)
STANDARD_DEVIATION 53.81 • n=4 Participants
|
178.24 centimeters per second (cm/s)
STANDARD_DEVIATION 57.19 • n=6 Participants
|
|
Splanchnic Vascular Velocity
Celiac Artery: EDV
|
43.20 centimeters per second (cm/s)
STANDARD_DEVIATION 14.95 • n=2 Participants
|
41.29 centimeters per second (cm/s)
STANDARD_DEVIATION 17.14 • n=4 Participants
|
42.25 centimeters per second (cm/s)
STANDARD_DEVIATION 15.96 • n=6 Participants
|
|
Splanchnic Vascular Velocity
Celiac Artery: TAMAX
|
87.60 centimeters per second (cm/s)
STANDARD_DEVIATION 30.53 • n=2 Participants
|
86.01 centimeters per second (cm/s)
STANDARD_DEVIATION 25.44 • n=4 Participants
|
86.81 centimeters per second (cm/s)
STANDARD_DEVIATION 27.84 • n=6 Participants
|
|
Splanchnic Blood Flow Volume
Superior Mesenteric Artery Volume Flow
|
626.62 ml/min
STANDARD_DEVIATION 286.01 • n=2 Participants
|
737.36 ml/min
STANDARD_DEVIATION 378.03 • n=4 Participants
|
681.99 ml/min
STANDARD_DEVIATION 337.28 • n=6 Participants
|
|
Splanchnic Blood Flow Volume
Celiac Artery Volume Flow
|
859.18 ml/min
STANDARD_DEVIATION 478.67 • n=2 Participants
|
963.94 ml/min
STANDARD_DEVIATION 466.00 • n=4 Participants
|
911.56 ml/min
STANDARD_DEVIATION 470.18 • n=6 Participants
|
|
Splanchnic Blood Flow Volume
Portal Vein Volume Flow
|
1661.75 ml/min
STANDARD_DEVIATION 817.59 • n=2 Participants
|
1812.50 ml/min
STANDARD_DEVIATION 973.27 • n=4 Participants
|
1737.13 ml/min
STANDARD_DEVIATION 891.75 • n=6 Participants
|
|
Serum Albumin
|
4.38 g/dL
STANDARD_DEVIATION 0.29 • n=2 Participants
|
4.23 g/dL
STANDARD_DEVIATION 0.48 • n=4 Participants
|
4.31 g/dL
STANDARD_DEVIATION 0.40 • n=6 Participants
|
PRIMARY outcome
Timeframe: Change from Baseline (week 0) at Week 16Population: All participants who underwent randomization were included in the final analysis according to the modified Intention-to-Treat (ITT) principle.
Heart rate variability (HRV) was assessed using a 15-minute resting ECG recording. This table reports three time-domain measures: 1) SDNN (Standard deviation of all NN intervals), 2) RMSSD (Root mean square of successive differences), and 3) SDANN (Standard deviation of the average NN intervals). These parameters reflect autonomic nervous system activity and cardiac vagal tone. All data are reported in milliseconds. Higher values indicate better autonomic regulation. Only these three time-domain parameters are presented in this table.
Outcome measures
| Measure |
Aerobic Exercise Group (AE)
n=23 Participants
Participants in the intervention group will undergo 150 minutes of moderate aerobic exercise per week for 16 weeks, accompanied by a personalized nutritional plan (1.2 grams of protein per kilogram of ideal body weight per day and a calorie intake of 35 kilocalories per kilogram of ideal body weight per day).
|
Control Group (CG)
n=21 Participants
The control group will solely receive nutritional guidance and maintain their physical inactivity.
|
|---|---|---|
|
Time-domain Heart Rate Variability (HRV) Parameters: SDNN and RMSSD and SDANN
SDNN
|
75.87 milliseconds
Interval 32.55 to 117.31
|
55.13 milliseconds
Interval 42.14 to 137.86
|
|
Time-domain Heart Rate Variability (HRV) Parameters: SDNN and RMSSD and SDANN
SDANN
|
-4.77 milliseconds
Interval -11.57 to 28.31
|
-14.91 milliseconds
Interval -60.63 to 19.36
|
|
Time-domain Heart Rate Variability (HRV) Parameters: SDNN and RMSSD and SDANN
RMSSD
|
-5.08 milliseconds
Interval -24.46 to 28.29
|
-28.61 milliseconds
Interval -60.59 to 5.66
|
PRIMARY outcome
Timeframe: Change from Baseline (week 0) at week 16A time-domain measure of heart rate variability (HRV) reflecting parasympathetic activity. It is calculated as the percentage of successive normal-to-normal (NN) intervals that differ by more than 50 milliseconds. Data were collected using 3-lead ECG during a 15-minute resting period."
Outcome measures
| Measure |
Aerobic Exercise Group (AE)
n=23 Participants
Participants in the intervention group will undergo 150 minutes of moderate aerobic exercise per week for 16 weeks, accompanied by a personalized nutritional plan (1.2 grams of protein per kilogram of ideal body weight per day and a calorie intake of 35 kilocalories per kilogram of ideal body weight per day).
|
Control Group (CG)
n=21 Participants
The control group will solely receive nutritional guidance and maintain their physical inactivity.
|
|---|---|---|
|
Time Domain Outcome: pNN50
|
0 percentage of successive NN intervals
Interval -15.55 to 4.76
|
0.86 percentage of successive NN intervals
Interval -7.71 to 3.69
|
PRIMARY outcome
Timeframe: Change from Baseline (week 0) at Week 16Assessment of frequency-domain components of heart rate variability, including Total Power (TF), High Frequency (HF), Low Frequency (LF), and Very Low Frequency (VLF). Analysis was performed using Adinstrument (tm) on a 15-minute ECG recording at rest. These parameters reflect the power distribution across different frequency bands and represent autonomic nervous system activity. Data presented in the table represent the change from baseline to Week 16.
Outcome measures
| Measure |
Aerobic Exercise Group (AE)
n=23 Participants
Participants in the intervention group will undergo 150 minutes of moderate aerobic exercise per week for 16 weeks, accompanied by a personalized nutritional plan (1.2 grams of protein per kilogram of ideal body weight per day and a calorie intake of 35 kilocalories per kilogram of ideal body weight per day).
|
Control Group (CG)
n=21 Participants
The control group will solely receive nutritional guidance and maintain their physical inactivity.
|
|---|---|---|
|
HRV Frequency Domain Measures: TP, HF, LF, VLF
High Frequency (HF)
|
-49.04 ms^2
Interval -714.52 to 1048.74
|
-174.58 ms^2
Interval -3864.3 to 78.04
|
|
HRV Frequency Domain Measures: TP, HF, LF, VLF
Total Frequency Power (TP)
|
-627.24 ms^2
Interval -8393.35 to 861.68
|
-626.90 ms^2
Interval -9040.66 to 4.87
|
|
HRV Frequency Domain Measures: TP, HF, LF, VLF
Low Frequency (LF)
|
-188.32 ms^2
Interval -2127.56 to 335.0
|
-392.99 ms^2
Interval -2991.63 to 160.24
|
|
HRV Frequency Domain Measures: TP, HF, LF, VLF
Very Low Frequency (VLF)
|
-436.11 ms^2
Interval -4111.51 to 343.63
|
-498.32 ms^2
Interval -912.69 to 531.54
|
PRIMARY outcome
Timeframe: Change from Baseline (week 0) and Week 16Categorical assessment of changes in autonomic function using the Ewing Autonomic Battery test. Participants are classified into three categories: 'Improved', 'No change', or 'Worsened' based on their composite score changes from baseline to Week 16. Results are reported as the number of participants in each category.
Outcome measures
| Measure |
Aerobic Exercise Group (AE)
n=23 Participants
Participants in the intervention group will undergo 150 minutes of moderate aerobic exercise per week for 16 weeks, accompanied by a personalized nutritional plan (1.2 grams of protein per kilogram of ideal body weight per day and a calorie intake of 35 kilocalories per kilogram of ideal body weight per day).
|
Control Group (CG)
n=21 Participants
The control group will solely receive nutritional guidance and maintain their physical inactivity.
|
|---|---|---|
|
Changes in Ewing Autonomic Battery Test Scores (Improved, No Change, Worsened)
Improved
|
7 Participants
|
10 Participants
|
|
Changes in Ewing Autonomic Battery Test Scores (Improved, No Change, Worsened)
No change
|
11 Participants
|
9 Participants
|
|
Changes in Ewing Autonomic Battery Test Scores (Improved, No Change, Worsened)
Worsened
|
5 Participants
|
2 Participants
|
PRIMARY outcome
Timeframe: Change from Baseline (week 0) at Week 16Assessment of the change in brachial artery flow-mediated dilation (FMD) from baseline to Week 16. FMD was determined by ultrasound as the percentage increase in arterial diameter during reactive hyperemia compared to baseline diameter. Results are reported as the percentage change (%). Positive values indicate an improvement in endothelial-dependent vasodilation.
Outcome measures
| Measure |
Aerobic Exercise Group (AE)
n=23 Participants
Participants in the intervention group will undergo 150 minutes of moderate aerobic exercise per week for 16 weeks, accompanied by a personalized nutritional plan (1.2 grams of protein per kilogram of ideal body weight per day and a calorie intake of 35 kilocalories per kilogram of ideal body weight per day).
|
Control Group (CG)
n=21 Participants
The control group will solely receive nutritional guidance and maintain their physical inactivity.
|
|---|---|---|
|
Endothelial Function Test: Change in Flow-mediated Dilation (FMD)
|
-1.17 % of FMD response
Standard Deviation 4.99
|
0.28 % of FMD response
Standard Deviation 3.99
|
PRIMARY outcome
Timeframe: Change from baseline (week 0) to week 16The LF/HF ratio is calculated as the ratio between the absolute power of the Low Frequency (LF) and High Frequency (HF) bands. It is used as an index of sympathovagal balance. Results are reported as a ratio (unitless).
Outcome measures
| Measure |
Aerobic Exercise Group (AE)
n=23 Participants
Participants in the intervention group will undergo 150 minutes of moderate aerobic exercise per week for 16 weeks, accompanied by a personalized nutritional plan (1.2 grams of protein per kilogram of ideal body weight per day and a calorie intake of 35 kilocalories per kilogram of ideal body weight per day).
|
Control Group (CG)
n=21 Participants
The control group will solely receive nutritional guidance and maintain their physical inactivity.
|
|---|---|---|
|
HRV Frequency Domain Measures: Low Frequency/High Frequency (LF/HF) Ratio
|
0.52 Ratio
Interval 0.42 to 2.09
|
0.53 Ratio
Interval 0.41 to 1.08
|
SECONDARY outcome
Timeframe: Change from Baseline (week 0) at week 16Lean appendicular mass (kg) from Dual energy X-ray absorptiometry (DXA)
Outcome measures
| Measure |
Aerobic Exercise Group (AE)
n=23 Participants
Participants in the intervention group will undergo 150 minutes of moderate aerobic exercise per week for 16 weeks, accompanied by a personalized nutritional plan (1.2 grams of protein per kilogram of ideal body weight per day and a calorie intake of 35 kilocalories per kilogram of ideal body weight per day).
|
Control Group (CG)
n=21 Participants
The control group will solely receive nutritional guidance and maintain their physical inactivity.
|
|---|---|---|
|
Muscle Mass Change
|
0.33 kg
Standard Deviation 1.62
|
-1.45 kg
Standard Deviation 0.9
|
SECONDARY outcome
Timeframe: Change from Baseline (week 0) at week 166-minute walk test (minute)
Outcome measures
| Measure |
Aerobic Exercise Group (AE)
n=23 Participants
Participants in the intervention group will undergo 150 minutes of moderate aerobic exercise per week for 16 weeks, accompanied by a personalized nutritional plan (1.2 grams of protein per kilogram of ideal body weight per day and a calorie intake of 35 kilocalories per kilogram of ideal body weight per day).
|
Control Group (CG)
n=21 Participants
The control group will solely receive nutritional guidance and maintain their physical inactivity.
|
|---|---|---|
|
Physical Function
|
24 meter
Interval 10.0 to 52.0
|
2 meter
Interval -23.0 to 13.0
|
SECONDARY outcome
Timeframe: Change from Baseline (week 0) at week 16Handgrip strength (kg) from dynamometer
Outcome measures
| Measure |
Aerobic Exercise Group (AE)
n=23 Participants
Participants in the intervention group will undergo 150 minutes of moderate aerobic exercise per week for 16 weeks, accompanied by a personalized nutritional plan (1.2 grams of protein per kilogram of ideal body weight per day and a calorie intake of 35 kilocalories per kilogram of ideal body weight per day).
|
Control Group (CG)
n=21 Participants
The control group will solely receive nutritional guidance and maintain their physical inactivity.
|
|---|---|---|
|
Muscle Strength Change
|
-1.80 Kg
Standard Deviation 3.24
|
0.39 Kg
Standard Deviation 3.59
|
SECONDARY outcome
Timeframe: Baseline and after 16-week interventionBlood-flow parameters derived from mesenteric Doppler ultrasound (celiac and superior mesenteric arteries, portal vein) were obtained as exploratory markers of splanchnic circulation.
Outcome measures
| Measure |
Aerobic Exercise Group (AE)
n=23 Participants
Participants in the intervention group will undergo 150 minutes of moderate aerobic exercise per week for 16 weeks, accompanied by a personalized nutritional plan (1.2 grams of protein per kilogram of ideal body weight per day and a calorie intake of 35 kilocalories per kilogram of ideal body weight per day).
|
Control Group (CG)
n=19 Participants
The control group will solely receive nutritional guidance and maintain their physical inactivity.
|
|---|---|---|
|
Splanchnic Volume Flow
Portal vein volume flow
|
312.67 mL/min
Standard Deviation 690.18
|
218.48 mL/min
Standard Deviation 315.05
|
|
Splanchnic Volume Flow
Celiac artery volume flow
|
167.63 mL/min
Standard Deviation 402.11
|
-5.46 mL/min
Standard Deviation 32.15
|
|
Splanchnic Volume Flow
Superior mesenteric artery volume flow
|
39.75 mL/min
Standard Deviation 180.35
|
66.03 mL/min
Standard Deviation 335.57
|
SECONDARY outcome
Timeframe: Baseline and Week 16Assessment of the correlation between the change in appendicular muscle mass index (measured by appendicular mass divided by height squared via Dual-Energy X-ray Absorptiometry; DXA) and the change in serum ammonia levels from baseline to week 16. Statistical significance is evaluated using Spearman's rank correlation coefficient for non-normally distributed data.
Outcome measures
| Measure |
Aerobic Exercise Group (AE)
n=23 Participants
Participants in the intervention group will undergo 150 minutes of moderate aerobic exercise per week for 16 weeks, accompanied by a personalized nutritional plan (1.2 grams of protein per kilogram of ideal body weight per day and a calorie intake of 35 kilocalories per kilogram of ideal body weight per day).
|
Control Group (CG)
n=21 Participants
The control group will solely receive nutritional guidance and maintain their physical inactivity.
|
|---|---|---|
|
The Association Between Changes in Muscle Mass and Changes in Serum Ammonia Levels
|
-0.052 Correlation coefficient
|
-0.40 Correlation coefficient
|
Adverse Events
Exercise Group
Control Group
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
Exercise Group
n=25 participants at risk
Participants in the intervention group will undergo 150 minutes of moderate aerobic exercise per week for 16 weeks, accompanied by a personalized nutritional plan (1.2 grams of protein per kilogram of ideal body weight per day and a calorie intake of 35 kilocalories per kilogram of ideal body weight per day).
|
Control Group
n=25 participants at risk
The control group will solely receive nutritional guidance and maintain their physical inactivity.
|
|---|---|---|
|
Musculoskeletal and connective tissue disorders
Muscle strain
|
4.0%
1/25 • from enrollment until end of follow-up, up to 16 week
|
0.00%
0/25 • from enrollment until end of follow-up, up to 16 week
|
|
Musculoskeletal and connective tissue disorders
Knee pain
|
20.0%
5/25 • from enrollment until end of follow-up, up to 16 week
|
0.00%
0/25 • from enrollment until end of follow-up, up to 16 week
|
Additional Information
Dr. Sirinda Kittiprachakul
Department of Rehabilitation Medicine, Faculty of Medicine, Chulalongkorn University
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place